메뉴 건너뛰기




Volumn 95, Issue 3, 2008, Pages 281-293

Antiangiogenic therapy and surgical practice

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOSTATIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; AXITINIB; BATIMASTAT; BEVACIZUMAB; CANSTATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; DEHYDRODIDEMNIN B; ENDOSTATIN; ERLOTINIB; GEFITINIB; INDOMETACIN; INTERLEUKIN 12; IRINOTECAN; MARIMASTAT; MONOCLONAL ANTIBODY IMC 1C11; MONOCLONAL ANTIBODY LM 609; OS 1574; SEMAXANIB; SORAFENIB; SUNITINIB; THROMBOSPONDIN 1; UNINDEXED DRUG; VANDETANIB; VATALANIB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

EID: 40749091298     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6108     Document Type: Review
Times cited : (10)

References (135)
  • 1
    • 0032893263 scopus 로고    scopus 로고
    • SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
    • Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
    • (1999) Cancer Res , vol.59 , pp. 99-106
    • Fong, T.A.1    Shawver, L.K.2    Sun, L.3    Tang, C.4    App, H.5    Powell, T.J.6
  • 2
    • 0035866771 scopus 로고    scopus 로고
    • Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
    • Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-2419.
    • (2001) Cancer Res , vol.61 , pp. 2413-2419
    • Geng, L.1    Donnelly, E.2    McMahon, G.3    Lin, P.C.4    Sierra-Rivera, E.5    Oshinka, H.6
  • 3
    • 0036242810 scopus 로고    scopus 로고
    • SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
    • Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002; 16: 681-690.
    • (2002) FASEB J , vol.16 , pp. 681-690
    • Laird, A.D.1    Christensen, J.G.2    Li, G.3    Carver, J.4    Smith, K.5    Xin, X.6
  • 4
    • 0041672482 scopus 로고    scopus 로고
    • SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models
    • Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-4016.
    • (2003) Cancer Res , vol.63 , pp. 4009-4016
    • Schueneman, A.J.1    Himmelfarb, E.2    Geng, L.3    Tan, J.4    Donnelly, E.5    Mendel, D.6
  • 5
    • 0037102369 scopus 로고    scopus 로고
    • ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    • Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
    • (2002) Cancer Res , vol.62 , pp. 4645-4655
    • Wedge, S.R.1    Ogilvie, D.J.2    Dukes, M.3    Kendrew, J.4    Chester, R.5    Jackson, J.A.6
  • 6
    • 0034655182 scopus 로고    scopus 로고
    • PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
    • Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
    • (2000) Cancer Res , vol.60 , pp. 2178-2189
    • Wood, J.M.1    Bold, G.2    Buchdunger, E.3    Cozens, R.4    Ferrari, S.5    Frei, J.6
  • 8
    • 10744222964 scopus 로고    scopus 로고
    • Pharmacological characterization of CP-547 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy
    • Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM et al. Pharmacological characterization of CP-547 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003; 63: 7301-7309.
    • (2003) Cancer Res , vol.63 , pp. 7301-7309
    • Beebe, J.S.1    Jani, J.P.2    Knauth, E.3    Goodwin, P.4    Higdon, C.5    Rossi, A.M.6
  • 9
    • 3042548695 scopus 로고    scopus 로고
    • Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
    • Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
    • (2004) Am J Pathol , vol.165 , pp. 35-52
    • Inai, T.1    Mancuso, M.2    Hashizume, H.3    Baffert, F.4    Haskell, A.5    Baluk, P.6
  • 10
    • 20144370978 scopus 로고    scopus 로고
    • AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
    • Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-4400.
    • (2005) Cancer Res , vol.65 , pp. 4389-4400
    • Wedge, S.R.1    Kendrew, J.2    Hennequin, L.F.3    Valentine, P.J.4    Barry, S.T.5    Brave, S.R.6
  • 11
    • 3142774878 scopus 로고    scopus 로고
    • AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
    • Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941.
    • (2004) Cancer Res , vol.64 , pp. 4931-4941
    • Traxler, P.1    Allegrini, P.R.2    Brandt, R.3    Brueggen, J.4    Cozens, R.5    Fabbro, D.6
  • 12
    • 20044375603 scopus 로고    scopus 로고
    • Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
    • Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345.
    • (2004) Angiogenesis , vol.7 , pp. 335-345
    • Wang, Y.1    Fei, D.2    Vanderlaan, M.3    Song, A.4
  • 13
    • 0037386937 scopus 로고    scopus 로고
    • A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma
    • Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003; 9: 1323-1332.
    • (2003) Clin Cancer Res , vol.9 , pp. 1323-1332
    • Posey, J.A.1    Ng, T.C.2    Yang, B.3    Khazaeli, M.B.4    Carpenter, M.D.5    Fox, F.6
  • 16
    • 85047695382 scopus 로고    scopus 로고
    • VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice
    • Kamiyama M, Ichikawa Y, Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y et al. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 2002; 9: 197-201.
    • (2002) Cancer Gene Ther , vol.9 , pp. 197-201
    • Kamiyama, M.1    Ichikawa, Y.2    Ishikawa, T.3    Chishima, T.4    Hasegawa, S.5    Hamaguchi, Y.6
  • 17
    • 33645838598 scopus 로고    scopus 로고
    • Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy
    • Levine AM, Tulpule A, Quinn DI, Gorospe G III, Smith DL, Hornor L et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24: 1712-1719.
    • (2006) J Clin Oncol , vol.24 , pp. 1712-1719
    • Levine, A.M.1    Tulpule, A.2    Quinn, D.I.3    Gorospe III, G.4    Smith, D.L.5    Hornor, L.6
  • 18
    • 7444261960 scopus 로고    scopus 로고
    • Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity
    • Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004; 4(Suppl 2): S81-S85.
    • (2004) Clin Colorectal Cancer , vol.4 , Issue.SUPPL. 2
    • Konner, J.1    Dupont, J.2
  • 19
    • 0031454617 scopus 로고    scopus 로고
    • Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
    • O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
    • (1997) Cell , vol.88 , pp. 277-285
    • O'Reilly, M.S.1    Boehm, T.2    Shing, Y.3    Fukai, N.4    Vasios, G.5    Lane, W.S.6
  • 20
    • 0038574455 scopus 로고    scopus 로고
    • Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells
    • Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997-1008.
    • (2003) Hum Gene Ther , vol.14 , pp. 997-1008
    • Dkhissi, F.1    Lu, H.2    Soria, C.3    Opolon, P.4    Griscelli, F.5    Liu, H.6
  • 21
    • 0032510801 scopus 로고    scopus 로고
    • Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
    • Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998; 95: 5579-5583.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 5579-5583
    • Claesson-Welsh, L.1    Welsh, M.2    Ito, N.3    Anand-Apte, B.4    Soker, S.5    Zetter, B.6
  • 23
    • 0035940429 scopus 로고    scopus 로고
    • Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor
    • Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001; 98: 12 485-12 490.
    • (2001) Proc Natl Acad Sci U S A , vol.98
    • Rodriguez-Manzaneque, J.C.1    Lane, T.F.2    Ortega, M.A.3    Hynes, R.O.4    Lawler, J.5    Iruela-Arispe, M.L.6
  • 24
    • 0010712792 scopus 로고    scopus 로고
    • Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
    • Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
    • (1998) Cell , vol.92 , pp. 391-400
    • Brooks, P.C.1    Silletti, S.2    von Schalscha, T.L.3    Friedlander, M.4    Cheresh, D.A.5
  • 25
    • 0032578703 scopus 로고    scopus 로고
    • IL-12 regulates VEGF and MMPs in a murine breast cancer model
    • Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361-365.
    • (1998) Int J Cancer , vol.78 , pp. 361-365
    • Dias, S.1    Boyd, R.2    Balkwill, F.3
  • 28
    • 0030500450 scopus 로고    scopus 로고
    • New perspectives in clinical oncology from angiogenesis research
    • Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-2539.
    • (1996) Eur J Cancer , vol.32 A , pp. 2534-2539
    • Folkman, J.1
  • 29
    • 0034307327 scopus 로고    scopus 로고
    • Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase
    • Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000; 60: 5410-5413.
    • (2000) Cancer Res , vol.60 , pp. 5410-5413
    • Kim, Y.M.1    Jang, J.W.2    Lee, O.H.3    Yeon, J.4    Choi, E.Y.5    Kim, K.W.6
  • 31
    • 0037969161 scopus 로고    scopus 로고
    • Endostatin action and intracellular signaling: Beta-catenin as a potential target?
    • Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action and intracellular signaling: beta-catenin as a potential target? Cancer Lett 2003; 196: 1-12.
    • (2003) Cancer Lett , vol.196 , pp. 1-12
    • Dixelius, J.1    Cross, M.J.2    Matsumoto, T.3    Claesson-Welsh, L.4
  • 32
    • 0141621070 scopus 로고    scopus 로고
    • Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity
    • Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003; 278: 37 895-37 901.
    • (2003) J Biol Chem , vol.278
    • Wickstrom, S.A.1    Alitalo, K.2    Keski-Oja, J.3
  • 33
    • 0037008721 scopus 로고    scopus 로고
    • Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1
    • Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277: 27 872-27 879.
    • (2002) J Biol Chem , vol.277
    • Kim, Y.M.1    Hwang, S.2    Kim, Y.M.3    Pyun, B.J.4    Kim, T.Y.5    Lee, S.T.6
  • 34
    • 33344472286 scopus 로고    scopus 로고
    • Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action
    • Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
    • (2006) Exp Cell Res , vol.312 , pp. 594-607
    • Folkman, J.1
  • 35
    • 0037372436 scopus 로고    scopus 로고
    • Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells
    • Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 2003; 101: 1857-1863.
    • (2003) Blood , vol.101 , pp. 1857-1863
    • Wajih, N.1    Sane, D.C.2
  • 36
    • 0037160991 scopus 로고    scopus 로고
    • Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study
    • Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359: 1019-1025.
    • (2002) Lancet , vol.359 , pp. 1019-1025
    • Yang, Q.1    Rasmussen, S.A.2    Friedman, J.M.3
  • 37
    • 0035667067 scopus 로고    scopus 로고
    • High serum endostatin levels in Down syndrome: Implications for improved treatment and prevention of solid tumours
    • Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001; 9: 811-814.
    • (2001) Eur J Hum Genet , vol.9 , pp. 811-814
    • Zorick, T.S.1    Mustacchi, Z.2    Bando, S.Y.3    Zatz, M.4    Moreira-Filho, C.A.5    Olsen, B.6
  • 38
    • 0037155610 scopus 로고    scopus 로고
    • Cancer therapy. Setbacks for endostatin
    • Marshall E. Cancer therapy. Setbacks for endostatin. Science 2002; 295: 2198-2199.
    • (2002) Science , vol.295 , pp. 2198-2199
    • Marshall, E.1
  • 39
  • 40
    • 34547106834 scopus 로고    scopus 로고
    • Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells
    • Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007; 361: 79-84.
    • (2007) Biochem Biophys Res Commun , vol.361 , pp. 79-84
    • Ling, Y.1    Yang, Y.2    Lu, N.3    You, Q.D.4    Wang, S.5    Gao, Y.6
  • 41
    • 0027383944 scopus 로고
    • Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
    • Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351-358.
    • (1993) J Cell Physiol , vol.157 , pp. 351-358
    • Murphy, A.N.1    Unsworth, E.J.2    Stetler-Stevenson, W.G.3
  • 42
    • 0042197340 scopus 로고    scopus 로고
    • TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism
    • Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114: 171-180.
    • (2003) Cell , vol.114 , pp. 171-180
    • Seo, D.W.1    Li, H.2    Guedez, L.3    Wingfield, P.T.4    Diaz, T.5    Salloum, R.6
  • 43
    • 0037393850 scopus 로고    scopus 로고
    • A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
    • Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407-415.
    • (2003) Nat Med , vol.9 , pp. 407-415
    • Qi, J.H.1    Ebrahem, Q.2    Moore, N.3    Murphy, G.4    Claesson-Welsh, L.5    Bond, M.6
  • 44
    • 11444266441 scopus 로고    scopus 로고
    • Cancer anti-angiogenic therapy
    • Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004; 27: 599-605.
    • (2004) Biol Pharm Bull , vol.27 , pp. 599-605
    • Shimizu, K.1    Oku, N.2
  • 46
    • 2442718070 scopus 로고    scopus 로고
    • Experimental study of the inhibitory effect of indomethacin on the growth and angiogenesis of human colon cancer xenografts
    • Wang HM, Zhang GY. Experimental study of the inhibitory effect of indomethacin on the growth and angiogenesis of human colon cancer xenografts. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 184-187.
    • (2004) Di Yi Jun Yi Da Xue Xue Bao , vol.24 , pp. 184-187
    • Wang, H.M.1    Zhang, G.Y.2
  • 47
    • 16644371877 scopus 로고    scopus 로고
    • Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells.]
    • Zhu HX, Zhang G, Wang YH, Zhou CQ, Bai JF, Xu NZ. [Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells.] Ai Zheng 2004; 23: 737-741.
    • (2004) Ai Zheng , vol.23 , pp. 737-741
    • Zhu, H.X.1    Zhang, G.2    Wang, Y.H.3    Zhou, C.Q.4    Bai, J.F.5    Xu, N.Z.6
  • 48
    • 33646241064 scopus 로고    scopus 로고
    • Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling
    • Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res 2006; 66: 4378-4384.
    • (2006) Cancer Res , vol.66 , pp. 4378-4384
    • Lee, A.1    Frischer, J.2    Serur, A.3    Huang, J.4    Bae, J.O.5    Kornfield, Z.N.6
  • 49
    • 0033870756 scopus 로고    scopus 로고
    • Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
    • Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6: 3056-3061.
    • (2000) Clin Cancer Res , vol.6 , pp. 3056-3061
    • Gutheil, J.C.1    Campbell, T.N.2    Pierce, P.R.3    Watkins, J.D.4    Huse, W.D.5    Bodkin, D.J.6
  • 50
    • 0035266184 scopus 로고    scopus 로고
    • Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist
    • Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yarernko B, Nechuta T et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res 2001; 61: 2232-2238.
    • (2001) Cancer Res , vol.61 , pp. 2232-2238
    • Kumar, C.C.1    Malkowski, M.2    Yin, Z.3    Tanghetti, E.4    Yarernko, B.5    Nechuta, T.6
  • 52
    • 0036570203 scopus 로고    scopus 로고
    • ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase
    • Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560.
    • (2002) Cancer Res , vol.62 , pp. 2554-2560
    • Hirata, A.1    Ogawa, S.2    Kometani, T.3    Kuwano, T.4    Naito, S.5    Kuwano, M.6
  • 53
    • 33644876381 scopus 로고    scopus 로고
    • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: The wave of the future in cancer therapy
    • Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 2005; 28: 481-486.
    • (2005) Cancer Nurs , vol.28 , pp. 481-486
    • Penne, K.1    Bohlin, C.2    Schneider, S.3    Allen, D.4
  • 54
    • 0033561522 scopus 로고    scopus 로고
    • Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
    • Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
    • (1999) Cancer Res , vol.59 , pp. 1935-1940
    • Huang, S.M.1    Bock, J.M.2    Harari, P.M.3
  • 55
    • 0033954292 scopus 로고    scopus 로고
    • Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
    • Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-715.
    • (2000) J Clin Oncol , vol.18 , pp. 708-715
    • Fine, H.A.1    Figg, W.D.2    Jaeckle, K.3    Wen, P.Y.4    Kyritsis, A.P.5    Loeffler, J.S.6
  • 56
    • 0035957682 scopus 로고    scopus 로고
    • Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect
    • Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001; 495: 159-166.
    • (2001) FEBS Lett , vol.495 , pp. 159-166
    • Vincent, L.1    Chen, W.2    Hong, L.3    Mirshahi, F.4    Mishal, Z.5    Mirshahi-Khorassani, T.6
  • 57
    • 0028344887 scopus 로고
    • Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470)
    • Yamamoto T, Sudo K, Fujita T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 1994; 14: 1-3.
    • (1994) Anticancer Res , vol.14 , pp. 1-3
    • Yamamoto, T.1    Sudo, K.2    Fujita, T.3
  • 58
    • 20244381828 scopus 로고    scopus 로고
    • Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin
    • Satchi-Fainaro R, Mamluk R, Wang L, Short SM, NagyJA, Feng D et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005; 7: 251-261.
    • (2005) Cancer Cell , vol.7 , pp. 251-261
    • Satchi-Fainaro, R.1    Mamluk, R.2    Wang, L.3    Short, S.M.4    Nagy, J.A.5    Feng, D.6
  • 59
    • 0034907881 scopus 로고    scopus 로고
    • The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor
    • Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-1078.
    • (2001) Clin Cancer Res , vol.7 , pp. 1073-1078
    • Yoshiji, H.1    Kuriyama, S.2    Kawata, M.3    Yoshii, J.4    Ikenaka, Y.5    Noguchi, R.6
  • 60
    • 11144239579 scopus 로고    scopus 로고
    • 2-Methoxyestradiol inhibits hypoxia-inducible factor 1 alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma
    • Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1 alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 2004; 10: 8665-8673.
    • (2004) Clin Cancer Res , vol.10 , pp. 8665-8673
    • Ricker, J.L.1    Chen, Z.2    Yang, X.P.3    Pribluda, V.S.4    Swartz, G.M.5    Van Waes, C.6
  • 62
    • 0036692153 scopus 로고    scopus 로고
    • The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis
    • Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 2002; 1: 795-802.
    • (2002) Mol Cancer Ther , vol.1 , pp. 795-802
    • Boivin, D.1    Gendron, S.2    Beaulieu, E.3    Gingras, D.4    Beliveau, R.5
  • 63
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 64
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6
  • 65
    • 27944458472 scopus 로고    scopus 로고
    • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer
    • Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 2005; 69(Suppl 3): 17-24.
    • (2005) Oncology , vol.69 , Issue.SUPPL. 3 , pp. 17-24
    • Hurwitz, H.1    Kabbinavar, F.2
  • 66
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 67
    • 50249185913 scopus 로고    scopus 로고
    • Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 San Antonio breast cancer symposium. Clin Adv Hematol Oncol 2007; 5: 1-12.
    • Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 San Antonio breast cancer symposium. Clin Adv Hematol Oncol 2007; 5: 1-12.
  • 68
    • 30944446883 scopus 로고    scopus 로고
    • Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    • Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
    • (2006) Nat Clin Pract Oncol , vol.3 , pp. 24-40
    • Jain, R.K.1    Duda, D.G.2    Clark, J.W.3    Loeffler, J.S.4
  • 71
    • 50249099861 scopus 로고    scopus 로고
    • Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25: (2007 ASCO Annual Meeting proceedings Part 1. 18S):LBA1.
    • Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25: (2007 ASCO Annual Meeting proceedings Part 1. 18S):LBA1.
  • 72
    • 84995908124 scopus 로고    scopus 로고
    • Bevacizumab and Cetuximab for the treatment of Metastatic Colorectal Cancer
    • National Insitute for Health and Clinical Excellence, accessed 4 October 2007
    • National Insitute for Health and Clinical Excellence. Bevacizumab and Cetuximab for the treatment of Metastatic Colorectal Cancer. NICE Technology Appraisal Guidance 118, 2007; http://www.nice.org.uk/nicemedia/pdf/word/ TA118GuidanceWord.doc [accessed 4 October 2007].
    • (2007) NICE Technology Appraisal Guidance , vol.118
  • 73
    • 33748985366 scopus 로고    scopus 로고
    • Intravitreal injection of Bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy
    • Mason JO III, Nixon PA, White MF. Intravitreal injection of Bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Opthalmol 2006; 142: 685-688.
    • (2006) Am J Opthalmol , vol.142 , pp. 685-688
    • Mason III, J.O.1    Nixon, P.A.2    White, M.F.3
  • 74
    • 33745782355 scopus 로고    scopus 로고
    • Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    • Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW JR et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
    • (2006) Retina , vol.26 , pp. 495-511
    • Rich, R.M.1    Rosenfeld, P.J.2    Puliafito, C.A.3    Dubovy, S.R.4    Davis, J.L.5    Flynn6    HW, J.R.7
  • 75
    • 33947732977 scopus 로고    scopus 로고
    • Angiogenesis: An organizing principle for drug discovery?
    • Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
    • (2007) Nat Rev Drug Discov , vol.6 , pp. 273-286
    • Folkman, J.1
  • 76
    • 0141988568 scopus 로고    scopus 로고
    • Fundamental concepts of the angiogenic process
    • Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-651.
    • (2003) Curr Mol Med , vol.3 , pp. 643-651
    • Folkman, J.1
  • 77
    • 0036088478 scopus 로고    scopus 로고
    • Mechanisms of normal and tumor-derived angiogenesis
    • Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-C970.
    • (2002) Am J Physiol Cell Physiol , vol.282
    • Papetti, M.1    Herman, I.M.2
  • 78
    • 0028865988 scopus 로고
    • Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
    • Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-6165.
    • (1995) Cancer Res , vol.55 , pp. 6161-6165
    • Mukhopadhyay, D.1    Tsiokas, L.2    Sukhatme, V.P.3
  • 79
    • 0031825702 scopus 로고    scopus 로고
    • Hypoxia-inducible factor 1: From molecular biology to cardiopulmonary physiology
    • Semenza GL, Agani F, Iyer N, Jiang BH, Leung S, Wiener C et al. Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest 1998; 114: (Suppl): 40S-45S.
    • (1998) Chest , vol.114 , Issue.SUPPL.
    • Semenza, G.L.1    Agani, F.2    Iyer, N.3    Jiang, B.H.4    Leung, S.5    Wiener, C.6
  • 80
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 81
    • 0023157363 scopus 로고
    • Angiogenic factors
    • Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.
    • (1987) Science , vol.235 , pp. 442-447
    • Folkman, J.1    Klagsbrun, M.2
  • 82
    • 33745171739 scopus 로고    scopus 로고
    • Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions
    • Ding S, Li C, Lin S, Yang Y, Liu D, Han Y et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006; 37: 861-866.
    • (2006) Hum Pathol , vol.37 , pp. 861-866
    • Ding, S.1    Li, C.2    Lin, S.3    Yang, Y.4    Liu, D.5    Han, Y.6
  • 83
    • 33745102388 scopus 로고    scopus 로고
    • Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
    • Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-1832.
    • (2006) Br J Cancer , vol.94 , pp. 1823-1832
    • Des Guetz, G.1    Uzzan, B.2    Nicolas, P.3    Cucherat, M.4    Morere, J.F.5    Benamouzig, R.6
  • 84
    • 27244431905 scopus 로고    scopus 로고
    • Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti-CD31 monoclonal antibody
    • Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 2005; 25: 201-206.
    • (2005) Neuropathology , vol.25 , pp. 201-206
    • Yao, Y.1    Kubota, T.2    Takeuchi, H.3    Sato, K.4
  • 85
    • 2342514123 scopus 로고    scopus 로고
    • Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis
    • Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64: 2941-2955.
    • (2004) Cancer Res , vol.64 , pp. 2941-2955
    • Uzzan, B.1    Nicolas, P.2    Cucherat, M.3    Perret, G.Y.4
  • 86
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 87
    • 33748923637 scopus 로고    scopus 로고
    • Dormant tumors awaken by a short-term angiogenic burst: The spike hypothesis
    • Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006; 5: 1751-1755.
    • (2006) Cell Cycle , vol.5 , pp. 1751-1755
    • Indraccolo, S.1    Favaro, E.2    Amadori, A.3
  • 88
    • 0034660890 scopus 로고    scopus 로고
    • Fractals and cancer
    • Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000; 60: 3683-3688.
    • (2000) Cancer Res , vol.60 , pp. 3683-3688
    • Baish, J.W.1    Jain, R.K.2
  • 89
    • 0023788067 scopus 로고
    • Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
    • Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
    • (1988) Am J Pathol , vol.133 , pp. 95-109
    • Dvorak, H.F.1    Nagy, J.A.2    Dvorak, J.T.3    Dvorak, A.M.4
  • 90
    • 0034161989 scopus 로고    scopus 로고
    • Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
    • Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
    • (2000) Cancer Res , vol.60 , pp. 1388-1393
    • Eberhard, A.1    Kahlert, S.2    Goede, V.3    Hemmerlein, B.4    Plate, K.H.5    Augustin, H.G.6
  • 91
    • 0242624629 scopus 로고    scopus 로고
    • Molecular basis of angiogenesis and cancer
    • Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22: 6549-6556.
    • (2003) Oncogene , vol.22 , pp. 6549-6556
    • Tonini, T.1    Rossi, F.2    Claudio, P.P.3
  • 92
    • 0028822834 scopus 로고
    • Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
    • Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
    • (1995) Cancer Res , vol.55 , pp. 4575-4580
    • Rak, J.1    Mitsuhashi, Y.2    Bayko, L.3    Filmus, J.4    Shirasawa, S.5    Sasazuki, T.6
  • 94
    • 0042972556 scopus 로고    scopus 로고
    • Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis
    • Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-231.
    • (2003) Cancer Cell , vol.3 , pp. 219-231
    • Watnick, R.S.1    Cheng, Y.N.2    Rangarajan, A.3    Ince, T.A.4    Weinberg, R.A.5
  • 95
    • 22944447177 scopus 로고    scopus 로고
    • Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy
    • Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005; 3: 413-423.
    • (2005) Mol Cancer Res , vol.3 , pp. 413-423
    • Fleming, J.B.1    Shen, G.L.2    Holloway, S.E.3    Davis, M.4    Brekken, R.A.5
  • 97
    • 33645907503 scopus 로고    scopus 로고
    • Inflammation and cancer: The role of the immune response and angiogenesis
    • Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res 2006; 130: 1-38.
    • (2006) Cancer Treat Res , vol.130 , pp. 1-38
    • Dalgleish, A.G.1    O'Byrne, K.2
  • 98
    • 0035902802 scopus 로고    scopus 로고
    • Chronic immune activation and inflammation as the cause of malignancy
    • O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85: 473-483.
    • (2001) Br J Cancer , vol.85 , pp. 473-483
    • O'Byrne, K.J.1    Dalgleish, A.G.2
  • 99
    • 0027970092 scopus 로고
    • Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
    • O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
    • (1994) Cell , vol.79 , pp. 315-328
    • O'Reilly, M.S.1    Holmgren, L.2    Shing, Y.3    Chen, C.4    Rosenthal, R.A.5    Moses, M.6
  • 100
    • 0029098530 scopus 로고
    • Antibody-directed targeting of the vasculature of solid tumors
    • Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995; 36: 237-251.
    • (1995) Breast Cancer Res Treat , vol.36 , pp. 237-251
    • Thorpe, P.E.1    Burrows, F.J.2
  • 102
    • 0036985699 scopus 로고    scopus 로고
    • Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications
    • Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(Suppl 16): 10-14.
    • (2002) Semin Oncol , vol.29 , Issue.SUPPL. 16 , pp. 10-14
    • Ferrara, N.1
  • 103
    • 34447258681 scopus 로고    scopus 로고
    • Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
    • Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-949.
    • (2007) J Cell Biochem , vol.101 , pp. 937-949
    • Fukumura, D.1    Jain, R.K.2
  • 104
    • 0023909330 scopus 로고
    • Determinants of tumor blood flow: A review
    • Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641-2658.
    • (1988) Cancer Res , vol.48 , pp. 2641-2658
    • Jain, R.K.1
  • 106
    • 0016437023 scopus 로고
    • Effect of fibrinogen on aggregation of red cells and on apparent viscosity of artificial thrombi in haemophilia, myocardial infarction, thyroid disease, cancer and control systems: Effect of ABO blood groups
    • Dintenfass L, Forbes CD. Effect of fibrinogen on aggregation of red cells and on apparent viscosity of artificial thrombi in haemophilia, myocardial infarction, thyroid disease, cancer and control systems: effect of ABO blood groups. Microvasc Res 1975; 9: 107-118.
    • (1975) Microvasc Res , vol.9 , pp. 107-118
    • Dintenfass, L.1    Forbes, C.D.2
  • 107
    • 0028025011 scopus 로고
    • Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows
    • Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994; 54: 4564-4568.
    • (1994) Cancer Res , vol.54 , pp. 4564-4568
    • Yuan, F.1    Salehi, H.A.2    Boucher, Y.3    Vasthare, U.S.4    Tuma, R.F.5    Jain, R.K.6
  • 108
    • 23444460271 scopus 로고    scopus 로고
    • Antiangiogenic therapy for cancer: Current and emerging concepts
    • Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005 19(Suppl 3):;7-16.
    • (2005) Oncology (Williston Park) , vol.19 , Issue.SUPPL. 3 , pp. 7-16
    • Jain, R.K.1
  • 109
    • 0035114055 scopus 로고    scopus 로고
    • The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer
    • Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 2001; 28: 93-105.
    • (2001) Semin Oncol , vol.28 , pp. 93-105
    • Los, M.1    Voest, E.E.2
  • 111
    • 0037141466 scopus 로고    scopus 로고
    • A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
    • Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 2002; 86: 1604-1614.
    • (2002) Br J Cancer , vol.86 , pp. 1604-1614
    • Hori, K.1    Saito, S.2    Kubota, K.3
  • 112
    • 2942593990 scopus 로고    scopus 로고
    • Anti-vascular tumor therapy: Recent advances, pitfalls and clinical perspectives
    • Eichhorn ME, Strieth S, Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat 2004; 7: 125-138.
    • (2004) Drug Resist Updat , vol.7 , pp. 125-138
    • Eichhorn, M.E.1    Strieth, S.2    Dellian, M.3
  • 113
    • 0035908479 scopus 로고    scopus 로고
    • Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment
    • Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93: 1040-1041.
    • (2001) J Natl Cancer Inst , vol.93 , pp. 1040-1041
    • Fidler, I.J.1
  • 114
    • 0032719528 scopus 로고    scopus 로고
    • Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
    • Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-2734.
    • (1999) Clin Cancer Res , vol.5 , pp. 2726-2734
    • Slaton, J.W.1    Perrotte, P.2    Inoue, K.3    Dinney, C.P.4    Fidler, I.J.5
  • 115
    • 0037251744 scopus 로고    scopus 로고
    • Resistance in the anti-angiogenic era: Nay-saying or a word of caution?
    • Sweeney CJ, Miller KD, Sledge GW JR. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003; 9: 24-29.
    • (2003) Trends Mol Med , vol.9 , pp. 24-29
    • Sweeney, C.J.1    Miller, K.D.2    Sledge, G.J.3
  • 116
    • 0034087691 scopus 로고    scopus 로고
    • Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
    • Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
    • (2000) J Clin Invest , vol.105
    • Klement, G.1    Baruchel, S.2    Rak, J.3    Man, S.4    Clark, K.5    Hicklin, D.J.6
  • 117
    • 33846441659 scopus 로고    scopus 로고
    • Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
    • Kamat AA, Kim TJ, Landen CN JR, Lu C, Han LY, Lin YG et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67: 281-288.
    • (2007) Cancer Res , vol.67 , pp. 281-288
    • Kamat, A.A.1    Kim, T.J.2    Landen3    CN, J.R.4    Lu, C.5    Han, L.Y.6    Lin, Y.G.7
  • 118
    • 0033580889 scopus 로고    scopus 로고
    • Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    • Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
    • (1999) Science , vol.284 , pp. 1994-1998
    • Holash, J.1    Maisonpierre, P.C.2    Compton, D.3    Boland, P.4    Alexander, C.R.5    Zagzag, D.6
  • 119
    • 0033529618 scopus 로고    scopus 로고
    • Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
    • Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
    • (1999) Circ Res , vol.85 , pp. 221-228
    • Asahara, T.1    Masuda, H.2    Takahashi, T.3    Kalka, C.4    Pastore, C.5    Silver, M.6
  • 120
    • 0032887340 scopus 로고    scopus 로고
    • Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
    • Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
    • (1999) Am J Pathol , vol.155 , pp. 739-752
    • Maniotis, A.J.1    Folberg, R.2    Hess, A.3    Seftor, E.A.4    Gardner, L.M.5    Pe'er, J.6
  • 123
    • 27644588474 scopus 로고    scopus 로고
    • Pancreatectomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: A pilot study
    • Hirota M, Shimada S, Yamamoto K, Tanaka E, Sugita H, Egami H et al. Pancreatectomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: a pilot study. JOP 2005; 6: 143-151.
    • (2005) JOP , vol.6 , pp. 143-151
    • Hirota, M.1    Shimada, S.2    Yamamoto, K.3    Tanaka, E.4    Sugita, H.5    Egami, H.6
  • 124
    • 0035064192 scopus 로고    scopus 로고
    • Premenopausal status accelerates relapse in node positive breast cancer: Hypothesis links angiogenesis, screening controversy
    • Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001; 65: 217-224.
    • (2001) Breast Cancer Res Treat , vol.65 , pp. 217-224
    • Retsky, M.1    Demicheli, R.2    Hrushesky, W.3
  • 125
    • 4344587881 scopus 로고    scopus 로고
    • Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
    • Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004; 6: R372-R374.
    • (2004) Breast Cancer Res , vol.6
    • Retsky, M.1    Bonadonna, G.2    Demicheli, R.3    Folkman, J.4    Hrushesky, W.5    Valagussa, P.6
  • 126
    • 0036219390 scopus 로고    scopus 로고
    • Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses
    • te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF et al. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 2002; 9: 303-309.
    • (2002) Ann Surg Oncol , vol.9 , pp. 303-309
    • te Velde, E.A.1    Voest, E.E.2    van Gorp, J.M.3    Verheem, A.4    Hagendoorn, J.5    Gebbink, M.F.6
  • 127
    • 0037963801 scopus 로고    scopus 로고
    • Neoadjuvant antiangiogenic therapy with tamoxifen does not impair gastrointestinal anastomotic repair in the rat
    • McNamara DA, Walsh TN, Kay E, Bouchier-Hayes DJ. Neoadjuvant antiangiogenic therapy with tamoxifen does not impair gastrointestinal anastomotic repair in the rat. Colorectal Dis 2003; 5: 335-341.
    • (2003) Colorectal Dis , vol.5 , pp. 335-341
    • McNamara, D.A.1    Walsh, T.N.2    Kay, E.3    Bouchier-Hayes, D.J.4
  • 129
    • 34347331382 scopus 로고    scopus 로고
    • Resection of hepatocellular carcinoma: The effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients
    • Tralhao JG, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007; 54: 1200-1206.
    • (2007) Hepatogastroenterology , vol.54 , pp. 1200-1206
    • Tralhao, J.G.1    Kayal, S.2    Dagher, I.3    Sanhueza, M.4    Vons, C.5    Franco, D.6
  • 130
    • 0031894878 scopus 로고    scopus 로고
    • Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer
    • Edna TH, Bjerkeset T. Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer. Dis Colon Rectum 1998; 41: 451-459.
    • (1998) Dis Colon Rectum , vol.41 , pp. 451-459
    • Edna, T.H.1    Bjerkeset, T.2
  • 133
    • 33847173683 scopus 로고    scopus 로고
    • Functional imaging of colorectal cancer angiogenesis
    • Goh V, Padhani AR, Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol 2007; 8: 245-255.
    • (2007) Lancet Oncol , vol.8 , pp. 245-255
    • Goh, V.1    Padhani, A.R.2    Rasheed, S.3
  • 134
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
    • (2004) Nat Med , vol.10 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    di Tomaso, E.3    Duda, D.G.4    Munn, L.L.5    Tong, R.T.6
  • 135
    • 0347615101 scopus 로고    scopus 로고
    • Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies
    • Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
    • (2003) J Clin Oncol , vol.21 , pp. 3955-3964
    • Morgan, B.1    Thomas, A.L.2    Drevs, J.3    Hennig, J.4    Buchert, M.5    Jivan, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.